
Catalyst Biosciences was a South San Francisco-based biopharmaceutical company focused on developing protein therapeutics for rare bleeding disorders including hemophilia. In 2023, GC Biopharma acquired Catalyst's rare hematology pipeline assets while Catalyst completed a reverse merger with GNI Group's Beijing Continent Pharmaceuticals, pivoting to fibrosis treatments.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account